# Centene Corporation – Consensus ‘buy’ rating and 13.7% Upside Potential

- Link: https://www.directorstalkinterviews.com/centene-corporation-consensus-buy-rating-and-13.7-upside-potential/4121132277
- Published: 2023-11-09T12:13:24+00:00
- Author: Charlotte Edwards

**Centene Corporation** which can be found using ticker (CNC) have now 16 market
analysts covering the stock. The analyst consensus now points to a rating of ‘buy’.
The target price High/Low ranges between $110.00 and $71.00 calculating the average
target price we see $81.56. Given that the stocks previous close was at $71.75 this
would imply there is now a potential upside of 13.7%. The day 50 moving average 
is $68.69 and the 200 day moving average is $67.67. The market capitalization for
the company is 37.56B. The stock price is currently at: $70.31 USD

 The potential market cap would be $42,695,004,629 based on the market consensus.

The company has a dividend yield of 1.57%. Other points of data to note are a P/
E ratio of 15.59, revenue per share of $253.50 and a 3.85% return on assets.

Centene Corporation is a healthcare company. The Company provides services to government-
sponsored and commercial healthcare programs, focusing on under-insured and uninsured
individuals. It provides a range of managed healthcare products and services, primarily
through Medicaid, Medicare, and commercial products. Its segments include Medicaid,
Medicare, Commercial and Other. It offers Medicaid and Medicare members (including
Medicare Prescription Drug Plans) as well as individuals and families served by 
the Health Insurance Marketplace and the TRICARE program. It also contracts with
other healthcare and commercial organizations to provide a variety of specialty 
services focused on treating the whole person. Medicaid program provides health 
insurance to low-income families and individuals with disabilities. Medicare is 
a federal health insurance program for people ages 65 and over, which also covers
people under 65 with certain disabilities and people with end-stage renal diseases.

Share on: